SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SharonAI Holdings, Inc. is a technology company. It focuses on high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings (SHAZ) is surging amidst community discussion following the release of an ambitious long-term roadmap outlining significant capacity expansion into 2028, further fueled by its association with the bullish AI sector and a notable photo of its co-founder with NVIDIA's CEO.

MKS, Inc. provides instruments, systems, subsystems and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes to improve process performance and productivity for its customers. It operates through the following segments: VSD (Vacuum Solutions Division), PSD (Photonics Solutions Division), and MSD (Materials Solutions Division). The VSD segment delivers foundational technology solutions to semiconductor manufacturing, electronics and packaging and specialty industrial applications. The PSD Segment provides a range of instruments, components and subsystems to edge semiconductor manufacturing, electronics and packaging and specialty industrial applications. The MSD segment develops process and manufacturing technologies for advanced surface modification, electroless and electrolytic plating, and surface finishing. The company was founded in 1961 and is headquartered in Andover, MA.

MKS Inc.

MKS Instruments, Inc.

MKS Instruments is trending as investors digest a mixed earnings report, where an EPS miss was overshadowed by strong revenue growth and optimistic guidance, reinforcing its position as a key enabler in the expanding AI and semiconductor capital equipment sector. The community is actively discussing its significant role in data center buildout and next-generation manufacturing, viewing it as an attractive long-term play despite some technical signals suggesting caution and recent convertible note offerings.

Berachain

Berachain (BERA) is heavily discussed as its innovative Proof-of-Liquidity (PoL) model and recent ecosystem upgrades, including new vaults and integrations, fuel optimism for a significant breakout. However, the community remains divided, with strong bullish sentiment clashing with warnings about volatility and concerns over token distribution.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

Heightened community discussion around recently resurfaced Jeffrey Epstein files, which some claim expose links to Bitcoin's early funding, is driving strong bearish sentiment and calls to short the cryptocurrency via BITI. This narrative fuels widespread speculation that Bitcoin is fundamentally flawed and poised for a significant decline.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed as its acquisition of Astria Therapeutics completes, integrating the late-stage HAE therapy navenibart into its pipeline just before upcoming earnings and new clinical data presentations. Community sentiment is mixed, balancing optimism for the strengthened rare disease portfolio against concerns over stock performance, perceived dilution, and significant short interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following robust Phase 2 axSpA clinical trial results for sonelokimab, described by the community as potentially "best-in-class" and generating significant buzz ahead of its Investor Day, amplifying discussions around substantial short interest and potential major acquisition interest.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies (EMAT) is trending with significant volatility and trading halts, fueled by its extremely low public float and widespread community discussion around its potential to secure a US-based critical minerals supply chain. Investors are actively debating short-term "pump and dump" risks versus a long-term opportunity, as the company aims to reduce reliance on China for rare earth materials.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending sharply higher after securing FDA approval for BYSANTI, a New Chemical Entity addressing Bipolar I Disorder and Schizophrenia with patent protection extending to 2044. The community is now highly focused on the stock's significant undervaluation, with widespread speculation of a major re-rating or buyout fueled by BYSANTI's market potential and the future 'mega blockbuster' prospects of its GLP-1 nausea drug candidate.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is seeing increased attention driven by the launch of its perpetuals DEX on Ethereum Mainnet, a prominent $1M trading competition, and key developments like the end of token inflation. The community is actively discussing the protocol's potential for price breakouts as it returns its core operations to Ethereum.

Fastenal Co. engages in the distribution of fasteners and tools. It also operates hardware stores. The company was founded by Robert A. Kierlin, Michael M. Gostomski, Henry K. McConnon, John D. Remick, and Stephen M. Slaggie in November 1967 and is headquartered in Winona, MN.

Fastenal Co.

Fastenal is trending following its recent earnings report, which, despite matching EPS, showed revenue falling short and highlighted persistent margin pressures in a sluggish industrial market. The community is keenly discussing these results and the implications of its announced 2-for-1 stock split.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Sells 116,575 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Jupiter Asset Management Ltd. decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 22.5% during the third quarter, according to the company in its most recent...

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 39.3% during the third quarter, according to its most recent filing...

Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Aberdeen Group plc lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 8.2% during the third quarter, according to the company in its most recent filing with...

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Public Sector Pension Investment Board boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 10.8% during the third quarter, according to the company in its...

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Allianz Asset Management GmbH cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 23.1% in the 3rd quarter, according to its most recent disclosure with the...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Current Price	$24.30
Prev Close	$24.42
Open	$24.40
Dividend Yield	0.00%
50-Day Moving Average	$23.78
Beta	0.99
Avg. Volume	1.23M
PE Ratio	14.18

52-Week High	$26.58
52-Week Low	$19.05
Market Capitalization	$2.99B
EPS (Annual)	$1.31
Price to Book	3.25
Revenue Per Employee	$2.72M

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc